Abstract: Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.
Type:
Grant
Filed:
March 5, 2007
Date of Patent:
September 20, 2011
Assignee:
Dianovix, Inc.
Inventors:
Virender Bhan, Andrea Hebb, Martin Holcik, Robert G. Korneluk, Craig Moore, George Robertson
Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
Type:
Application
Filed:
November 17, 2010
Publication date:
June 9, 2011
Applicant:
Dianovix, Inc.
Inventors:
Virender BHAN, John Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
Abstract: Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.
Type:
Grant
Filed:
February 6, 2007
Date of Patent:
December 28, 2010
Assignee:
Dianovix, Inc.
Inventors:
Virender Bhan, John W. Gillard, Andrea Hebb, Martin Holcik, Robert G. Korneluk, George Robertson
© 2025 Justia
